# SciFluor Life Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scifluor-life-sciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.scifluor.com
- Total disclosed funding: $5M
- Latest round: Series A (May 17, 2011)
- Investors on record: 1

## About

SciFluor Life Sciences develops innovative small molecule therapeutics focusing on unmet medical needs, particularly in ophthalmology, neurology, and fibrosis, by utilizing proprietary fluorine-based medicinal chemistry for improved treatment outcomes.Founded in 2011, SciFluor Life Sciences is based in Boston, US. The company specializes in creating small molecule therapeutic candidates. Notably, it raised USD 30.00 mn in April 2015 from investors including Allied Minds, Invesco, and Woodford Patient Capital Trust, marking its latest funding round. The firm’s strategic direction has remained focused on advancing its therapeutic pipeline since inception.SciFluor Life Sciences focuses on developing innovative small molecule therapeutic candidates primarily targeting unmet medical needs in ophthalmology, fibrosis, and neurology. The company's lead product, SF0166, is specifically designed to treat retinal diseases such as Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wet-AMD) through a topical eye drop formulation. SciFluor employs proprietary fluorine-based medicinal chemistry to enhance the potency, selectivity, and pharmacokinetic profiles of its products, which enables improved treatment outcomes. The company's expanding pipeline includes early-stage research initiatives in fibrosis and neurological disorders, showcasing its commitment to delivering novel therapeutic options. SciFluor distributes its products in various geographical markets, including North America, Europe, and select regions in Asia, catering to healthcare professionals, research institutions, and pharmaceutical companies.SciFluor Life Sciences generates revenue through partnerships and collaborations with various players in the biotechnology and pharmaceutical sectors. The company's transaction structure primarily consists of business-to-business (B2B) arrangements, where it supplies its innovative therapeutic candidates and associated services to research institutions and healthcare providers. Revenue is derived from licensing agreements, joint ventures, and potentially milestone payments linked to the clinical development of its products. Given the nature of the biotechnology sector, these transactions often involve negotiation of terms that align with the development phases of SciFluor's flagship products, such as SF0166. The company’s commitment to a robust intellectual property portfolio further supports its revenue-generating capabilities by providing a strong foundation for potential licensing agreements and collaborations.SciFluor Life Sciences plans to leverage the recent funding of USD 30.00 mn raised in April 2015 to continue its development of SF0166 and explore additional therapeutic candidates in its pipeline. The company aims to expand its market presence in North America and Europe, with target timelines for market entry and product launches set for the next few years. The funding will be utilized to support ongoing clinical trials and research initiatives focused on addressing significant medical needs in ophthalmology and other therapeutic areas.

## Funding rounds

- Series A, May 17, 2011, $5M — Allied Minds

## Investors

- Allied Minds (https://capitalatlas.ai/funds/allied-minds) — Series A